MICHELLE A FANALE to Cost-Benefit Analysis
This is a "connection" page, showing publications MICHELLE A FANALE has written about Cost-Benefit Analysis.
Connection Strength
0.134
-
Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL. Am J Manag Care. 2020 02 01; 26(2):e41-e49.
Score: 0.134
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.